1. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
- Author
-
Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M, Orlandi EM, Albano F, Galimberti S, Iurlo A, Pregno P, Sgherza N, Martino B, Binotto G, Castagnetti F, Gozzini A, Bocchia M, Fozza C, Stagno F, Simula MP, De Gregorio F, Trawinska MM, Scaffidi L, Elena C, Attolico I, Baratè C, Cattaneo D, Pirillo F, Gugliotta G, Sicuranza A, Molica M, La Nasa G, Foà R, and Breccia M
- Subjects
- Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Female, Humans, Italy epidemiology, Life Expectancy, Long Term Adverse Effects chemically induced, Long Term Adverse Effects mortality, Male, Mortality, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Risk Adjustment methods, Aniline Compounds administration & dosage, Aniline Compounds adverse effects, Cardiotoxicity etiology, Cardiotoxicity mortality, Cardiotoxicity prevention & control, Cardiovascular Diseases chemically induced, Cardiovascular Diseases mortality, Cardiovascular Diseases prevention & control, Dasatinib administration & dosage, Dasatinib adverse effects, Imidazoles administration & dosage, Imidazoles adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Nitriles administration & dosage, Nitriles adverse effects, Pyridazines administration & dosage, Pyridazines adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Quinolines administration & dosage, Quinolines adverse effects
- Abstract
Background: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2
ndG /3rdG TKIs) in the real-life practice., Methods: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib., Results: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control., Conclusion: Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF